"COVID Testing is for ages 18 and up, with first symptom starting in past 5-6 days. Scheduled Appts Only, No Walk Ins (Due to supply chain) COVID Research Programs: Vaccine, Testing, Outpatient Treatment, and Household Prevention. No Costs, No Insurance, New Treatments, Possible Compensation"

During the past decade, Suffolk Multispecialty Research conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 4 clinical trials were completed, i.e. on average, 44.4% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 3 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Suffolk Multispecialty Research" #1 sponsor was "Shire" with 3 trials, followed by "Bavarian Nordic" with 1 trials sponsored, "Ironwood Pharmaceuticals, Inc." with 1 trials sponsored, "Janssen Research & Development, LLC" with 1 trials sponsored and "Kowa Research Institute, Inc." with 1 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Suffolk Multispecialty Research" #1 collaborator was "Brigham and Women's Hospital" with 1 trials as a collaborator and "Takeda Development Center Americas, Inc." with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Suffolk Multispecialty Research" are "Diabetes Mellitus, Type 2" (2 trials), "Ulcerative Colitis" (2 trials), "COVID-19" (1 trials), "COVID-19 Disease" (1 trials) and "Crohn's Disease" (1 trials). Many other conditions were trialed in "Suffolk Multispecialty Research" in a lesser frequency.

Most popular intervention types in "Suffolk Multispecialty Research" are "Drug" (8 trials), "Biological" (2 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "25 mg Ontamalimab" (1 trials), "75 mg Ontamalimab" (1 trials), "ABNCoV2" (1 trials) and "Alogliptin Benzoate" (1 trials). Other intervention names were less common.

The vast majority of trials in "Suffolk Multispecialty Research" are 11 trials for "All" genders.

Currently, there are NaN active trials in "Suffolk Multispecialty Research". undefined are not yet recruiting, undefined are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Suffolk Multispecialty Research, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Suffolk Multispecialty Research, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".